Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00483730
Status:
COMPLETED
Last Update Posted:
2012-05-07
First Post:
2007-06-06
Brief Title:
Actovegin Versus Placebo in Patients With Diabetic Polyneuropathy AV-007-IM
Sponsor:
Nycomed
Organization:
Nycomed
Study Overview
Official Title:
A Multi-centre Double-blind Placebo-controlled Randomised Parallel Group Clinical Trial to Evaluate Efficacy and Safety of Actovegin in Diabetic Type 2 Patients With Symptomatic Diabetic Peripheral Polyneuropathy
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess clinical efficacy and safety of Actovegin in type 2 diabetic patients with symptomatic diabetic peripheral polyneuropathy after 250 ml iv infusions once daily for 20 days followed by oral treatment 600 mg 3 daily for 140 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None